The United States has launched a formal investigation into Germany under Section 301 of the Trade Act of 1974, examining whether the country’s pricing policies for innovative pharmaceutical products are discriminatory
The US Defense Department's designation of WuXi AppTec as a company linked to the Chinese military could disrupt pharmaceutical supply chains, impact American drugmakers, and put billions in revenue at risk.
